US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Caris Life Sciences, Inc. (CAI): AI Cancer TechBio Company Surges Six Points at Open

Caris Life Sciences, Inc. (CAI): VC-Backed AI TechBio Company Seeks $5b+ IPO Valuation

Caris Life Sciences, Inc. (CAI): Peeking at the Prospectus of an AI TechBio IPO

IPOs and Secondary Offerings

Equity Capital Markets

Caris Life Sciences / Equity Capital Markets

<ul>
<li>Caris Life Sciences increased the price range on its IPO on Monday ahead of a Wednesday scheduled debut.</li>
<li>According to our sources, the deal is multiple-times oversubscribed with a mix of new and existing investors. There are multiple mutual-fund anchor orders in the book.</li>
<li>Given how important this company’s technology is to the cancer arena and the revenue growth  that is “ramping” into the IPO, we like the risk-reward profile of this deal.</li>
</ul>


Caris Life Sciences increased the price range on its IPO on Monday ahead of a Wednesday scheduled debut.
According to our sources, the deal is multiple-times oversubscribed with a mix of new and existing investors. There are multiple mutual-fund anchor orders in the book.
Given how important this company’s technology is to the cancer arena and the revenue growth  that is “ramping” into the IPO, we like the risk-reward profile of this deal.


Caris Life Sciences, Inc. (CAI): Price Bumped Higher, Intersection of Cancer and AI in High Demand